BIOLOGY OF FLT3 LIGAND AND RECEPTOR

被引:0
|
作者
LYMAN, SD
机构
关键词
FLT3; LIGAND; STEM CELLS; TYROSINE KINASE RECEPTORS;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The flt3 ligand is a member of a small family of growth factors that stimulate the proliferation of hematopoietic cells; other members of this family include Steel factor (also known as mast cell growth factor, stem cell factor, and kit ligand) and colony stimulating factor 1. These proteins function by binding to and activating unique tyrosine kinase receptors. Expression of the flt3 receptor is primarily restricted among hematopoietic cells to the most primitive progenitor cells. The flt3 ligand is similar to Steel factor in that both proteins stimulate the proliferation of early progenitor or stem cells. Neither of these factors has much proliferative activity on its own, but each factor can synergize with a wide range of other colony stimulating factors and interleukins (ILs) to stimulate proliferation. One major difference between the two factors appears to be their effect on mast cells, which Steel factor stimulates but flt3 ligand does not. Although flt3 ligand and Steel factor each act on early hematopoietic cells, differences in their activities suggest that they are not redundant and both are required for normal hematopoiesis. There are a number of clinical settings in which the flt3 ligand may potentially prove quite useful.
引用
收藏
页码:63 / 73
页数:11
相关论文
共 50 条
  • [31] Antileukemic activity of Flt3 ligand in murine leukemia
    Wang, A
    Braun, SE
    Sonpavde, G
    Cornetta, K
    CANCER RESEARCH, 2000, 60 (07) : 1895 - 1900
  • [32] Structure-function analysis of FLT3 ligand-FLT3 receptor interactions using a rapid functional screen
    Graddis, TJ
    Brasel, K
    Friend, D
    Srinivasan, S
    Wee, SF
    Lyman, SD
    March, CJ
    McGrew, JT
    JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (28) : 17626 - 17633
  • [33] Safety of FLT3 ligand in healthy volunteers.
    Lebsack, ME
    McKenna, HJ
    Hoek, JA
    Hanna, R
    Feng, A
    Marashovsky, E
    Hayes, FA
    BLOOD, 1997, 90 (10) : 751 - 751
  • [34] Generation of dendritic cells in vivo with Flt3 ligand
    Caron, D
    Roux, E
    Teepe, M
    McKenna, H
    Maraskovsky, E
    ANNALS OF ONCOLOGY, 1998, 9 : 7 - 7
  • [35] THE ROLE OF FLT3 LIGAND IN EARLY MURINE HEMATOPOIESIS
    DEVRIES, P
    BRASEL, KA
    MCKENNA, HJ
    WILLIAMS, DE
    LYMAN, SD
    BLOOD, 1994, 84 (10) : A279 - A279
  • [36] FLT3 Inhibitors in Mutant FLT3 AML
    Stone, Richard M.
    Garcia, Jacqueline
    ANNALS OF HEMATOLOGY, 2017, 96 : S36 - S37
  • [37] Resistance to Selective FLT3 Inhibitors, Driven by FLT3 Ligand and FLT3 Point Mutations, Can Be Overcome with the Dual FLT3-Aurora Kinase Inhibitor CCT241736
    Moore, Andrew S.
    Faisal, Amir
    Bavetsias, Vassilios
    de Castro, David Gonzalez
    Sun, Chongbo
    Atrash, Butrus
    Valenti, Melanie
    Brandon, Alexis de Haven
    Avery, Sian
    Pearson, Andrew D. J.
    Workman, Paul
    Blagg, Julian
    Raynaud, Florence I.
    Eccles, Suzanne A.
    Linardopoulos, Spiros
    BLOOD, 2011, 118 (21) : 1490 - 1490
  • [38] Increased Plasma FLT3 Ligand Levels Following Chemotherapy May Interfere with the Clinical Efficacy of FLT3 Inhibitors
    Sato, Takashi
    Knapper, Steven
    Burnett, Alan K.
    White, Paul
    Levis, Mark
    BLOOD, 2009, 114 (22) : 387 - 387
  • [39] Wild-type FLT3 and FLT3 ITD exhibit similar ligand-induced internalization characteristics
    Kellner, Fabienne
    Keil, Andreas
    Schindler, Katrin
    Tschongov, Todor
    Huenninger, Kerstin
    Loercher, Hannah
    Rhein, Peter
    Boehmer, Sylvia-Annette
    Boehmer, Frank-D.
    Mueller, Joerg P.
    JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2020, 24 (08) : 4668 - 4676
  • [40] The Flt3L/Flt3 Axis in Dendritic Cell Biology and Cancer Immunotherapy
    Cueto, Francisco J.
    Sancho, David
    CANCERS, 2021, 13 (07)